Emerging diagnostics and therapeutics for Alzheimer disease

Lecanemab in early Alzheimer's disease

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · see citing works

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575 · see citing works

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · see citing works

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · see citing works

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · see citing works

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · see citing works

The molecular pathology of Alzheimer's disease

Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708 · see citing works

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works

Candidate gene for the chromosome 1 familial Alzheimer’s disease locus

Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498 · see citing works

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works

Cryo-EM structures of tau filaments from Alzheimer’s disease

Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061 · see citing works

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · see citing works

Amyloid β-peptide is produced by cultured cells during normal metabolism

Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · see citing works

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works

TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model

Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · see citing works

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · see citing works

Single App knock-in mouse models of Alzheimer’s disease

Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,447 · see citing works

Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type

Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I. M., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,380 · see citing works

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · see citing works

Synergy between amyloid-β and tau in Alzheimer’s disease

Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242 · see citing works

Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation

Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · see citing works

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease

Zhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., Poliani, P. L., Cominelli, M., Grover, S., Gilfillan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0695-9 · Cited by 1,150 · see citing works

Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease

Gate, D., Saligrama, N., Leventhal, O., Yang, A. C., Unger, M. S., Middeldorp, J., Chen, K., Lehallier, B., Channappa, D., De Los Santos, M. B., et al. (2020) · Nature · doi:10.1038/s41586-019-1895-7 · Cited by 992 · see citing works

Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · see citing works

Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease

Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., Qian, X., Laláková, J., Kühnemund, M., Voytyuk, I., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.038 · Cited by 949 · see citing works

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Spangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939 · see citing works

Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota

Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901 · see citing works

TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy

Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817 · see citing works

Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease

Rogers, J., Luber-Narod, J., Styren, S. D., & Civin, W. H. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80079-4 · Cited by 743 · see citing works

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease

Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688 · see citing works

Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease

Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · see citing works

Alzheimer’s disease drug development pipeline: 2022

Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665 · see citing works

CNS small vessel disease

Cannistraro, R. J., Badi, M. K., Eidelman, B. H., Dickson, D. W., Middlebrooks, E. H., & Meschia, J. F. (2019) · Neurology · doi:10.1212/wnl.0000000000007654 · Cited by 655 · see citing works

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651 · see citing works

Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation

He, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645 · see citing works

Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease

Morabito, S., Miyoshi, E., Michael, N., Shahin, S., Martini, A. C., Head, E., Silva, J., Leavy, K., Perez-Rosendahl, M., & Swarup, V. (2021) · Nature Genetics · doi:10.1038/s41588-021-00894-z · Cited by 643 · see citing works

Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy

Chen, X., Firulyova, M., Manis, M., Herz, J., Smirnov, I., Aladyeva, E., Wang, C., Bao, X., Finn, M. B., Hu, H., et al. (2023) · Nature · doi:10.1038/s41586-023-05788-0 · Cited by 609 · see citing works

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607 · see citing works

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598 · see citing works

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Wang, C., & Holtzman, D. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 589 · see citing works

Tau Kinetics in Neurons and the Human Central Nervous System

Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype

Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570 · see citing works

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · see citing works

Alzheimer's disease drug development pipeline: 2017

Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · see citing works

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model

Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200785 · Cited by 549 · see citing works

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545 · see citing works

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522 · see citing works

TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy

Leyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · see citing works

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · see citing works

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496 · see citing works

APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes

Blanchard, J. W., Akay, L. A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S. M., Effenberger, A., Chen, C.-Y., Maner-Smith, K., Hajjar, I., et al. (2022) · Nature · doi:10.1038/s41586-022-05439-w · Cited by 493 · see citing works

Microglial activation and tau propagate jointly across Braak stages

Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490 · see citing works

Performance of plasma phosphorylated tau 181 and 217 in the community

Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465 · see citing works

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

Shi, Y., Manis, M., Long, J., Wang, K., Sullivan, P. M., Remolina Serrano, J., Hoyle, R., & Holtzman, D. M. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190980 · Cited by 448 · see citing works

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · see citing works

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435 · see citing works

Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy

Da Mesquita, S., Papadopoulos, Z., Dykstra, T., Brase, L., Farias, F. G., Wall, M., Jiang, H., Kodira, C. D., de Lima, K. A., Herz, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03489-0 · Cited by 431 · see citing works

Exercise plasma boosts memory and dampens brain inflammation via clusterin

De Miguel, Z., Khoury, N., Betley, M. J., Lehallier, B., Willoughby, D., Olsson, N., Yang, A. C., Hahn, O., Lu, N., Vest, R. T., et al. (2021) · Nature · doi:10.1038/s41586-021-04183-x · Cited by 422 · see citing works

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 413 · see citing works

Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease

Sosna, J., Philipp, S., Albay, R., Reyes-Ruiz, J. M., Baglietto-Vargas, D., LaFerla, F. M., & Glabe, C. G. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0244-x · Cited by 406 · see citing works

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works

TDP-43 Pathology in Alzheimer’s Disease

Meneses, A. D., Koga, S., O’Leary, J., Dickson, D. W., Bu, G., & Zhao, N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00503-x · Cited by 360 · see citing works

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359 · see citing works

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02326-3 · Cited by 347 · see citing works

Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.03.024 · Cited by 334 · see citing works

TREM2 function impedes tau seeding in neuritic plaques

Leyns, C. E. G., Gratuze, M., Narasimhan, S., Jain, N., Koscal, L. J., Jiang, H., Manis, M., Colonna, M., Lee, V. M. Y., Ulrich, J. D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0433-0 · Cited by 332 · see citing works

γ-Secretase in Alzheimer’s disease

Hur, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 325 · see citing works

Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid

Drieu, A., Du, S., Storck, S. E., Rustenhoven, J., Papadopoulos, Z., Dykstra, T., Zhong, F., Kim, K., Blackburn, S., Mamuladze, T., et al. (2022) · Nature · doi:10.1038/s41586-022-05397-3 · Cited by 325 · see citing works

Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease

McAlpine, C. S., Park, J., Griciuc, A., Kim, E., Choi, S. H., Iwamoto, Y., Kiss, M. G., Christie, K. A., Vinegoni, C., Poller, W. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03734-6 · Cited by 322 · see citing works

The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works

Emerging roles of innate and adaptive immunity in Alzheimer’s disease

Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297 · see citing works

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer’s disease

De Schepper, S., Ge, J. Z., Sierksma, A., Crowley, G., Ferreira, L. S. S., Garceau, D., Toomey, C. E., Sokolova, D., Rueda-Carrasco, J., Shin, S.-H., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01257-z · Cited by 295 · see citing works

Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1ΔE9 murine model of Alzheimer’s disease

Minter, M. R., Hinterleitner, R., Meisel, M., Zhang, C., Leone, V., Zhang, X., Oyler-Castrillo, P., Zhang, X., Musch, M. W., Shen, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11047-w · Cited by 292 · see citing works

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Rafii, M. S., Sperling, R. A., Donohue, M. C., Zhou, J., Roberts, C., Irizarry, M. C., Dhadda, S., Sethuraman, G., Kramer, L. D., Swanson, C. J., et al. (2023) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12748 · Cited by 291 · see citing works

Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders

Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., Wang, F., Bradley, J. L., Eiffert, B., Bahena, J. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00886-6 · Cited by 290 · see citing works

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored

Chandra, S., Sisodia, S. S., & Vassar, R. J. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00595-7 · Cited by 278 · see citing works

Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases.

Xiang, X., Wind, K., Wiedemann, T., Blume, T., Shi, Y., Briel, N., Beyer, L., Biechele, G., Eckenweber, F., Zatcepin, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe5640 · Cited by 268 · see citing works

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Chapleau, M., Iaccarino, L., Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263195 · Cited by 264 · see citing works

Cerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease

Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160722 · Cited by 263 · see citing works

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

González‐Ortiz, F., Turton, M., Kac, P. R., Smirnov, D. S., Premi, E., Ghidoni, R., Benussi, L., Cantoni, V., Saraceno, C., Rivolta, J., et al. (2022) · Brain · doi:10.1093/brain/awac407 · Cited by 261 · see citing works

ApoE isoform– and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy

Seo, D.-O., O’Donnell, D., Jain, N., Ulrich, J. D., Herz, J., Li, Y., Lemieux, M., Cheng, J., Hu, H., Serrano, J. R., et al. (2023) · Science · doi:10.1126/science.add1236 · Cited by 254 · see citing works

Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration

Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252 · see citing works

Retromer in Alzheimer disease, Parkinson disease and other neurological disorders

Small, S. A., & Petsko, G. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn3896 · Cited by 235 · see citing works

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice

Mancuso, R., Fryatt, G., Cleal, M., Obst, J., Pipi, E., Monzón-Sandoval, J., Ribe, E., Winchester, L., Webber, C., Nevado, A., et al. (2019) · Brain · doi:10.1093/brain/awz241 · Cited by 235 · see citing works

Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke

Reish, N. J., Jamshidi, P., Stamm, B. J., Flanagan, M. E., Sugg, E., Tang, M., Donohue, K. L., McCord, M., Krumpelman, C. S., Mesulam, M. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2215148 · Cited by 234 · see citing works

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H. M., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2909 · Cited by 230 · see citing works

Activated microglia mitigate Aβ-associated tau seeding and spreading

Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Serrano, J. R., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210542 · Cited by 215 · see citing works

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration

Ryu, J. K., Rafalski, V. A., Meyer-Franke, A., Adams, R. A., Poda, S. B., Rios Coronado, P. E., Pedersen, L. Ø., Menon, V., Baeten, K. M., Sikorski, S. L., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0232-x · Cited by 213 · see citing works

Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau but Not with Amyloid Pathology: An Immunohistochemical Study

Merlini, M., Kirabali, T., Kulic, L., Nitsch, R. M., & Ferretti, M. T. (2018) · Neurodegenerative Diseases · doi:10.1159/000486200 · Cited by 209 · see citing works

Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis

Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209 · see citing works

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease

Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blendstrup, M., Bohorquez, S. M. S., Wildsmith, K. R., Toth, B., Dolton, M. J., Ramakrishnan, V., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1375 · Cited by 204 · see citing works

Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies

Bargar, C., Wang, W., Gunzler, S. A., LeFevre, A. N., Wang, Z., Lerner, A. J., Singh, N., Tatsuoka, C. M., Appleby, B. S., Zhu, X., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01175-w · Cited by 203 · see citing works

Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment

Piehl, N., van Olst, L., Ramakrishnan, A., Teregulova, V., Simonton, B., Zhang, Z., Tapp, E., Channappa, D., Oh, H. S., Losada, P. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.019 · Cited by 195 · see citing works

Age-dependent formation of TMEM106B amyloid filaments in human brains

Schweighauser, M., Arseni, D., Bacioglu, M., Huang, M., Lövestam, S., Shi, Y., Yang, Y., Zhang, W., Kotecha, A., Garringer, H. J., et al. (2022) · Nature · doi:10.1038/s41586-022-04650-z · Cited by 194 · see citing works

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

Li, Y., Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Weiner, M. W., Shaw, L. M. J., Masters, C. L., Fowler, C. J., Trojanowski, J. Q., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013211 · Cited by 194 · see citing works

Regional Aβ-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading

Lee, W. J., Brown, J. A., Kim, H. R., Joie, R. L., Cho, H., Lyoo, C. H., Rabinovici, G. D., Seong, J., & Seeley, W. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.034 · Cited by 193 · see citing works

TREM2 dependent and independent functions of microglia in Alzheimer’s disease

Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191 · see citing works

Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.

Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189 · see citing works

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works

APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function

Xiong, M., Jiang, H., Serrano, J. R., Gonzales, E. R., Wang, C., Gratuze, M., Hoyle, R., Bien-Ly, N., Silverman, A. P., Sullivan, P. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7522 · Cited by 179 · see citing works

Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice

Kiani Shabestari, S., Morabito, S., Danhash, E. P., McQuade, A., Sanchez, J. R., Miyoshi, E., Chadarevian, J. P., Claes, C., Coburn, M. A., Hasselmann, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110961 · Cited by 167 · see citing works

Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation

Antolini, L., DiFrancesco, J. C., Zedde, M., Basso, G., Arighi, A., Shima, A., Cagnin, A., Caulo, M., Carare, R. O., Charidimou, A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012778 · Cited by 158 · see citing works

Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer’s disease

Zeng, H., Huang, J., Zhou, H., Meilandt, W. J., Dejanovic, B., Zhou, Y., Bohlen, C. J., Lee, S.-H., Ren, J., Liu, A., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01251-x · Cited by 157 · see citing works

PLD3 affects axonal spheroids and network defects in Alzheimer’s disease

Yuan, P., Zhang, M., Tong, L., Morse, T. M., McDougal, R. A., Ding, H., Chan, D., Cai, Y., & Grutzendler, J. (2022) · Nature · doi:10.1038/s41586-022-05491-6 · Cited by 155 · see citing works

Insights into Alzheimer’s disease from single-cell genomic approaches

Murdock, M. H., & Tsai, L.-H. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01222-2 · Cited by 148 · see citing works

Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading

Jain, N., Lewis, C. A., Ulrich, J. D., & Holtzman, D. M. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220654 · Cited by 146 · see citing works

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Florian, H., Wang, D., Arnold, S. E., Boada, M., Guo, Q., Jin, Z., Zheng, H., Fisseha, N., Kalluri, H. V., Rendenbach‐Mueller, B., et al. (2023) · Brain · doi:10.1093/brain/awad024 · Cited by 137 · see citing works

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133 · see citing works

Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132 · see citing works

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

Strikwerda‐Brown, C., Hobbs, D. A., Gonneaud, J., St‐Onge, F., Binette, A. P., Ozlen, H., Provost, K., Soucy, J., Buckley, R. F., Benzinger, T. L. S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2379 · Cited by 129 · see citing works

In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease

Meisl, G., Hidari, E., Allinson, K., Rittman, T., DeVos, S. L., Sanchez, J. S., Xu, C. K., Duff, K. E., Johnson, K. A., Rowe, J. B., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh1448 · Cited by 127 · see citing works

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia

Xia, D., Lianoglou, S., Sandmann, T., Calvert, M., Suh, J. H., Thomsen, E., Dugas, J., Pizzo, M. E., DeVos, S. L., Earr, T. K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00547-7 · Cited by 124 · see citing works

TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.

Gratuze, M., Schlachetzki, J. C. M., D’Oliveira Albanus, R., Jain, N., Novotny, B., Brase, L., Rodriguez, L., Mansel, C., Kipnis, M., O’Brien, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.022 · Cited by 115 · see citing works

Resurrecting the Mysteries of Big Tau

Fischer, I., & Baas, P. W. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.04.007 · Cited by 113 · see citing works

Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool

Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111 · see citing works

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.07.007 · Cited by 108 · see citing works

Medin co-aggregates with vascular amyloid-β in Alzheimer’s disease

Wagner, J., Degenhardt, K., Veit, M., Louros, N. N., Konstantoulea, K., Skodras, A., Wild, K., Liu, P., Obermüller, U., Bansal, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05440-3 · Cited by 106 · see citing works

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology

Blennow, K., Chen, C., Cicognola, C., Wildsmith, K. R., Manser, P. T., Bohorquez, S. M. S., Zhang, Z., Xie, B., Peng, J., Hansson, O., et al. (2020) · Brain · doi:10.1093/brain/awz346 · Cited by 105 · see citing works

Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis

Jansen, W., Ossenkoppele, R., Knol, D., Tijms, B., Scheltens, P., Fr, V., Visser, P. J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., et al. (2015) · Archive ouverte UNIGE (University of Geneva) · Cited by 94 · see citing works

Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model

Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91 · see citing works

Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition

Chatterjee, P., Vermunt, L., Gordon, B. A., Pedrini, S., Boonkamp, L., Armstrong, N. J., Xiong, C., Singh, A. K., Li, Y., Sohrabi, H. R., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12879 · Cited by 89 · see citing works

Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation

Morioka, S., Kajioka, D., Yamaoka, Y., Ellison, R. M., Tufan, T., Werkman, I. L., Tanaka, S., Barron, B. J., Ito, S., Kucenas, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.029 · Cited by 84 · see citing works

Single nucleus multiomics identifies ZEB1 and MAFB as candidate regulators of Alzheimer’s disease-specific cis-regulatory elements

Anderson, A. G., Rogers, B. B., Loupe, J. M., Rodriguez-Nunez, I., Roberts, S. C., White, L. M., Brazell, J. N., Bunney, W. E., Bunney, B. G., Watson, S. J., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100263 · Cited by 82 · see citing works

Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study

van Arendonk, J., Neitzel, J., Steketee, R. M. E., van Assema, D. M. E., Vrooman, H. A., Segbers, M., Ikram, M. A., & Vernooij, M. W. (2022) · Brain · doi:10.1093/brain/awac354 · Cited by 82 · see citing works

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention

Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Towards PET imaging of the dynamic phenotypes of microglia

Beaino, W., Janssen, B., Vugts, D. J., de Vries, H. E., & Windhorst, A. D. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13649 · Cited by 61 · see citing works

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

Chhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60 · see citing works

Comparison of plasma and CSF biomarkers in predicting cognitive decline

Aschenbrenner, A. J., Li, Y., Henson, R. L., Volluz, K., Hassenstab, J. J., Verghese, P. B., West, T., Meyer, M. R., Kirmess, K. M., Fagan, A. M., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51670 · Cited by 59 · see citing works

A neuronal blood marker is associated with mortality in old age

Kaeser, S. A., Lehallier, B., Thinggaard, M., Häsler, L. M., Apel, A., Bergmann, C., Berdnik, D., Jeune, B., Christensen, K., Grönke, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00028-4 · Cited by 57 · see citing works

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

Boerwinkle, A. H., Gordon, B. A., Wisch, J., Flores, S., Henson, R. L., Butt, O. H., McKay, N., Chen, C. D., Benzinger, T. L. S., Fagan, A. M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00408-2 · Cited by 55 · see citing works

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease

Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S. N., Ewers, M., Haass, C., Brendel, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216987 · Cited by 55 · see citing works

Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease

Aguillon, D., Langella, S., Chen, Y., Sanchez, J. S., Su, Y., Vila‐Castelar, C., Vasquez, D., Zetterberg, H., Hansson, O., Dage, J. L., et al. (2023) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12906 · Cited by 54 · see citing works

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial

Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., Sabbagh, M. N., Yuan, S. H., Rissman, R. A., Pulsifer, M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0983 · Cited by 52 · see citing works

Generalizability of findings from a clinical sample to a community‐based sample: A comparison of ADNI and ARIC

Gianattasio, K. Z., Bennett, E. E., Wei, J., Mehrotra, M., Mosley, T. H., Gottesman, R. F., Wong, D. F., Stuart, E. A., Griswold, M. E., Couper, D. J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12293 · Cited by 51 · see citing works

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU ‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

Joseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wáng, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 48 · see citing works

CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer’s disease

Halbgebauer, S., Steinacker, P., Hengge, S., Oeckl, P., Abu‐Rumeileh, S., Anderl‐Straub, S., Lombardi, J., Arnim, C. A. F. V., Giese, A., Ludolph, A. C., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328646 · Cited by 46 · see citing works

Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease

Duong, M. T., Das, S. R., Lyu, X., Xie, L., Richardson, H., Xie, S. X., Yushkevich, P. A., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28941-1 · Cited by 44 · see citing works

A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALSPreprint

Irwin, K. E., Jasin, P., Braunstein, K. E., Sinha, I. R., Bowden, K. D., Moghekar, A., Oh, E. S., Raitcheva, D., Bartlett, D., Berry, J. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.23.525202 · Cited by 36 · see citing works

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals

Simrén, J., Brum, W. S., Ashton, N. J., Benedet, A. L., Karikari, T. K., Kvartsberg, H., Sjons, E., Lussier, F. Z., Chamoun, M., Stevenson, J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01142-0 · Cited by 33 · see citing works

Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas

Verma, N., Velmurugan, G. V., Winford, E. D., Ly, H., Kotiya, D., Leibold, N. S., Radulescu, L., Despa, S. I., Chen, K. C., Eldik, L. J. V., et al. (2023) · Communications Biology · doi:10.1038/s42003-022-04398-2 · Cited by 25 · see citing works

Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseasesPreprint

Nutma, E., Fancy, N. N., Weinert, M., Marzin, M. C., Tsartsalis, S., Muirhead, R. C. J., Falk, I. N., de Bruin, J., Hollaus, D., Pieterman, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.11.491453 · Cited by 11 · see citing works

Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression

Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11 · see citing works

Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease

Musiek, E. S., McDade, E., & Holtzman, D. M. (2023) · Annals of Neurology · doi:10.1002/ana.26643 · Cited by 9 · see citing works

ABI3 Is a Novel Early Biomarker of Alzheimer’s Disease

Cao, M., Liu, J., Zhang, X., Yang, T., Wang, Y., Hou, Y., Qiao, S., Cui, Y., Wang, Y., & Wang, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215635 · Cited by 8 · see citing works

Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab

Reyderman, L., Hayato, S., Reddy, H., Takenaka, O., Yasuda, S., Swanson, C. J., Willis, B. A., & Hussein, Z. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.069402 · Cited by 6 · see citing works

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy

Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 454 · see citing works

Radiopharmaceuticals and their applications in medicine

Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 317 · see citing works

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 220 · see citing works

Innate immune activation in neurodegenerative diseases

Castro‐Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 167 · see citing works

The six brain‐specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes

Buchholz, S., & Zempel, H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13784 · Cited by 145 · see citing works

Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer’s Disease

Jiang, S., Cai, G., Yang, Z., Shi, H., Zeng, H., Ye, Q., Hu, Z., & Wang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c13150 · Cited by 133 · see citing works

APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread

Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.029 · Cited by 120 · see citing works

Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank

Wang, X., Shi, Z., Qiu, Y., Sun, D., & Zhou, H. (2024) · BMC Medicine · doi:10.1186/s12916-024-03418-8 · Cited by 115 · see citing works

Lecanemab Treatment in a Specialty Memory Clinic

Paczynski, M., Hofmann, A., Posey, Z. J., Gregersen, M., Rudman, M., Ellington, D., Aldinger, M., Musiek, E. S., Holtzman, D. M., Bateman, R. J., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1232 · Cited by 116 · see citing works

Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease

Conn, K. A., Borsom, E. M., & Cope, E. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2371950 · Cited by 105 · see citing works

The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease

Quan, S., Fu, X., Cai, H., Ren, Z., Xu, Y., & Jia, L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00815-2 · Cited by 107 · see citing works

Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy

Wolk, D. A., Nelson, P. T., Apostolova, L. G., Arfanakis, K., Boyle, P. A., Carlsson, C. M., Corriveau‐Lecavalier, N., Dacks, P. A., Dickerson, B. C., Domoto‐Reilly, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14202 · Cited by 100 · see citing works

Sex-dependent APOE4 neutrophil–microglia interactions drive cognitive impairment in Alzheimer’s disease

Rosenzweig, N., Kleemann, K. L., Rust, T., Carpenter, M., Grucci, M., Aronchik, M., Brouwer, N., Valenbreder, I., Cooper-Hohn, J., Iyer, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03122-3 · Cited by 90 · see citing works

Lanthanide-bimetallic organic frameworks: from mechanism and sensors design to ratiometric fluorescent applications

Zhou, J., Hu, X., Liu, C., Liu, Y., Tian, N., Wu, F. Y., Li, W., Lei, J., & Dai, Z. H. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216574 · Cited by 91 · see citing works

Artificial intelligence for drug discovery and development in Alzheimer's disease

Qiu, Y., & Cheng, F. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102776 · Cited by 83 · see citing works

Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis

Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78 · see citing works

Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease

Rajani, R. M., Ellingford, R., Hellmuth, M., Harris, S. S., Taso, O. S., Graykowski, D., Lam, F. K. W., Arber, C., Fertan, E., Danial, J. S. H., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002727 · Cited by 57 · see citing works

Cryo-EM structures of Aβ40 filaments from the leptomeninges of individuals with Alzheimer’s disease and cerebral amyloid angiopathy

Yang, Y., Murzin, A. G., Peak‐Chew, S., Franco, C. D. M. F., Garringer, H. J., Newell, K. L., Ghetti, B. F., Goedert, M., & Scheres, S. H. W. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01694-8 · Cited by 59 · see citing works

Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflammation in Alzheimer’s disease

Song, Z., Xie, X., Chen, Y., Zhang, B., Li, X., Yang, Y., Mo, W., Zhang, J., & Xu, D. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.024 · Cited by 58 · see citing works

Adaptive immune changes associate with clinical progression of Alzheimer’s disease

van Olst, L., Kamermans, A., Halters, S., van der Pol, S. M. A., Rodríguez, E., Verberk, I. M. W., Verberk, S. G. S., Wessels, D. W. R., Rodriguez-Mogeda, C., Verhoeff, J., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00726-8 · Cited by 52 · see citing works

α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders

Hatano, T., Okuzumi, A., Matsumoto, G., Tsunemi, T., & Hattori, N. (2024) · Journal of Movement Disorders · doi:10.14802/jmd.24075 · Cited by 48 · see citing works

The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity

Arslan, B., Brum, W. S., Pola, I., Therriault, J., Rahmouni, N., Stevenson, J., Servaes, S., Tan, K., Vitali, P., Montembeault, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01692-z · Cited by 50 · see citing works

Metagenomic analysis characterizes stage-specific gut microbiota in Alzheimer’s disease

Jia, L., Ke, Y., Zhao, S., Liu, J., Luo, X., Cao, J., Liu, Y., Guo, Q., Chen, W., Chen, F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02973-7 · Cited by 47 · see citing works

Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

Langerscheidt, F., Wied, T., Kabbani, M. A. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 45 · see citing works

Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model

Hou, J., Chen, Y., Cai, Z., Heo, G. S., Yuede, C. M., Wang, Z., Lin, K., Saadi, F., Tršan, T., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9052 · Cited by 43 · see citing works

Astrocyte and oligodendrocyte pathology in Alzheimer's disease

Ziar, R., Tesar, P. J., & Clayton, B. L. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00540 · Cited by 47 · see citing works

SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis

Ouyang, P., Cai, Z., Peng, J., Lin, S., Chen, X., Chen, C., Feng, Z., Wang, L., Song, G.-L., & Zhang, Z. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103064 · Cited by 40 · see citing works

Rational structural design of aromatic Azo photoactive small molecules for biomedical applications

Ding, J., Huang, Z. H., Zhang, D., Qu, Y., Zhang, S., Zhang, C., Fang, B., Li, L., & Huang, W. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00334b · Cited by 38 · see citing works

Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease

Dicarlo, M., Pignataro, P., Zecca, C., Dell’Abate, M. T., Urso, D., Gnoni, V., Giugno, A., Borlizzi, F., Zerlotin, R., Oranger, A., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26946 · Cited by 35 · see citing works

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

Hofmann, A., Häsler, L. M., Lambert, M., Kaeser, S. A., Gräber‐Sultan, S., Obermüller, U., Kuder-Buletta, E., la Fougère, C. J., Laske, C., Vöglein, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52937-8 · Cited by 35 · see citing works

The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons

Sharma, M., Pal, P., & Gupta, S. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148797 · Cited by 33 · see citing works

Phototherapy via Modulation of β‐Amyloid in Combating Alzheimer's Disease

Zhang, Y., Qian, C., Chen, Y., He, W., & Guo, Z. (2025) · Aggregate · doi:10.1002/agt2.70020 · Cited by 31 · see citing works

Deciphering proteins in Alzheimer’s disease: A new Mendelian randomization method integrated with AlphaFold3 for 3D structure prediction

Yao, M., Miller, G. W., Vardarajan, B. N., Baccarelli, A., Guo, Z., & Liu, Z. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100700 · Cited by 33 · see citing works

Association between periodontitis and Alzheimer's disease: A narrative review

Seyedmoalemi, M., & Saied‐Moallemi, Z. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.004 · Cited by 29 · see citing works

Early-stage Alzheimer’s disease profiling in blood achieved by multiplexing aptamer-SERS biosensors

Muhammad, M., Liu, C., Ge, Y., Shao, C., Xiong, L., Xia, H., Iqbal, J., Zhan, J., Qu, F., & Huang, Q. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116907 · Cited by 28 · see citing works

Beyond the usual suspects: multi-factorial computational models in the search for neurodegenerative disease mechanisms

Khan, A. F., & Iturria‐Medina, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03073-w · Cited by 28 · see citing works

Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis

Antonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 28 · see citing works

Unlocking therapeutic potential: the role of adamantane in drug discovery

Dane, C., Cumbers, G. A., Allen, B. M., Montgomery, A. P., Danon, J. J., & Kassiou, M. (2024) · Australian Journal of Chemistry · doi:10.1071/ch24075 · Cited by 26 · see citing works

Omnidirectional improvement of mitochondrial health in Alzheimer's disease by multi-targeting engineered activated neutrophil exosomes

Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26 · see citing works

Pharmacological effects, molecular mechanisms and strategies to improve bioavailability of curcumin in the treatment of neurodegenerative diseases

Wang, G., Zhou, X., Pang, X., Ma, K., Li, L., Song, Y., Hou, D., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1625821 · Cited by 26 · see citing works

Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community

Valletta, M., Vetrano, D. L., Gregorio, C., Rizzuto, D., Winblad, B. G., Canevelli, M., Andersson, S., Dale, M., Fredolini, C., Laukka, E. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66728-2 · Cited by 30 · see citing works

Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function

Sadlon, A., Takousis, P., Ankli, B., Alexopoulos, P., Perneczky, R., & Initiative, A. D. N. (2023) · Annals of Neurology · doi:10.1002/ana.26804 · Cited by 25 · see citing works

APOE3ch alleviates Aβ and tau pathology and neurodegeneration in the human APPNL-G-F cerebral organoid model of Alzheimer’s disease

Liu, H., Mei, F., Ye, R., Han, X., Wang, S., Ding, Y., Zhi, Y., Pang, K., Guo, W., & Lu, B. (2024) · Cell Research · doi:10.1038/s41422-024-00957-w · Cited by 25 · see citing works

Roseburia intestinalis Supplementation Could Reverse the Learning and Memory Impairment and m6A Methylation Modification Decrease Caused by 27-Hydroxycholesterol in Mice

Sun, X., Zhou, C. L., Ju, M., Feng, W., Guo, Z., Qi, C., Yang, K., & Xiao, R. (2024) · Nutrients · doi:10.3390/nu16091288 · Cited by 25 · see citing works

Advanced biomarkers: Beyond amyloid and tau: Emerging non-traditional biomarkers for alzheimer`s diagnosis and progression

Afrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102736 · Cited by 24 · see citing works

Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway

Zhai, Y., Lu, K., Yuan, Y., Zhang, Z., Xue, L., Zhao, F., Xu, X., & Wang, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329439 · Cited by 24 · see citing works

FDCNN-AS: Federated deep convolutional neural network Alzheimer detection schemes for different age groups

Lakhan, A. R., Mohammed, M. A., Ghani, M. K. A., Abdulkareem, K. H., Marhoon, H. A., Nedoma, J., Martínek, R., & Deveci, M. (2024) · Information Sciences · doi:10.1016/j.ins.2024.120833 · Cited by 22 · see citing works

Development of donepezil hydrochloride-loaded PLGA-based nanoparticles for Alzheimer’s disease treatment

Kömür, M., Kıyan, H. T., & Öztürk, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95792-3 · Cited by 22 · see citing works

Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy

Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 24 · see citing works

Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia

Marvi, F., Chen, Y.-H., & Sawan, M. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3376835 · Cited by 23 · see citing works

Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2

Wang, J., Du, L., Zhang, T., Chu, Y., Wang, Y., Wang, Y. T., Ji, X., Kang, Y., Cui, R., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110006 · Cited by 22 · see citing works

Porphyromonas gingivalis and Its Outer Membrane Vesicles Induce Neuroinflammation in Mice Through Distinct Mechanisms

Qiu, Y. L., Zhao, Y., He, G., & Yang, D. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70135 · Cited by 21 · see citing works

Alzheimer’s disease and age-related macular degeneration: Shared and distinct immune mechanisms

Butovsky, O., & Rosenzweig, N. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.013 · Cited by 22 · see citing works

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort

Gong, K., Timsina, J., Ali, M., Chen, Y., Liu, M., Wang, C., Pottier, C. P., Feld, G. K., Heo, G., Benzinger, T. L. S., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00909-x · Cited by 21 · see citing works

Gut microbiota metabolites: potential therapeutic targets for Alzheimer’s disease?

Zhang, S., Lu, J., Jin, Z., Xu, H., Zhang, D., Chen, J., & Wang, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1459655 · Cited by 24 · see citing works

New insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies

Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19 · see citing works

Fueling the fight against cancer: Exploring the impact of branched-chain amino acid catalyzation on cancer and cancer immune microenvironment

Ma, Q., Li, H., Song, Z., Deng, Z., Huang, W., & Liu, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156016 · Cited by 18 · see citing works

ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine

Quan, Z., Wang, S., Xie, H., Zhang, J., Duan, R., Li, M., & Zhang, J. (2024) · Small · doi:10.1002/smll.202410031 · Cited by 18 · see citing works

Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models

Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 23 · see citing works

Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential

Borrego-Ruiz, A., & Borrego, J. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090724 · Cited by 20 · see citing works

Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)

Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 17 · see citing works

Regulation of STING G-quadruplex for rescuing cellular senescence and Aβ phagocytic capacity of microglia

Yuan, H., Yang, J., Qin, G., Sun, Y., Zhao, C., Wang, C., Ren, J., & Qu, X. (2024) · Chemical Science · doi:10.1039/d4sc04453c · Cited by 17 · see citing works

A Self‐Reinforced “Microglia Energy Modulator” for Synergistic Amyloid‐β Clearance in Alzheimer's Disease Model

Ma, M., Wang, J., Guo, K., Zhong, W., Cheng, Y., Lin, L., & Zhao, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202420547 · Cited by 17 · see citing works

Rational Design of Long-Circulating Bright Fluorescent Probe for In Vivo Imaging of Amyloid-β Plaques in Alzheimer’s Disease

Chen, J., Wang, X., Liu, X., Shi, L., Yu, X., Cen, X., & Li, K. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01619 · Cited by 16 · see citing works

Photothermal and Photodynamic Strategies for Diagnosis and Therapy of Alzheimer’s Disease by Modulating Amyloid-β Aggregation

Gao, F., Hou, Y., Wang, Y., Liu, L., Yi, X., & Xia, N. (2025) · Biosensors · doi:10.3390/bios15080480 · Cited by 15 · see citing works

Immunity in Alzheimer’s disease: From mechanisms to therapies

Chen, X., Holtzman, D. M., & Colonna, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.004 · Cited by 17 · see citing works

Alzheimer’s disease and immunotherapy

Qin, W., Pang, Y., Nie, S., Quan, M., & Jia, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00035-8 · Cited by 15 · see citing works

Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis

Oddi, S., Scipioni, L., Totaro, A., Giacovazzo, G., Ciaramellano, F., Tortolani, D., Leuti, A., Businaro, R., Armeli, F., Bilkei‐Gorzó, A., et al. (2025) · FEBS Journal · doi:10.1111/febs.17403 · Cited by 14 · see citing works

Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up

Knezović, A., & Šalković‐Petrišić, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02887-2 · Cited by 14 · see citing works

Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease

Yan, Z.-J., Ye, M., Li, J., Zhang, D., & Yao, Y. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00853-w · Cited by 15 · see citing works

A systems approach uncovers drivers of the multifocal emergence of an astrocyte state contributing to cognitive decline in Alzheimer’s diseasePreprint

Comandante-Lou, N., Lama, T. D., Heuer, S. E., Chen, K. W., Kim, J., Zhang, J., Hu, B., Liu, S., Dey, S., Brennand, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.24.639868 · Cited by 13 · see citing works

The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand

Thanapornsangsuth, P., Booncharoen, K., Khieukhajee, J., Luechaipanit, W., Haethaisong, T., Chongsuksantikul, A., Supharatpariyakorn, T., Chunharas, C., Likitjaroen, Y., & Hemachudha, T. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14138 · Cited by 13 · see citing works

Nasal nanotherapeutics for central nervous system disorders: Bridging the translational gap in central nervous system drug delivery

Zhang, Y.-B., Liu, M., Wang, Y., Hu, D., Wu, S., Zhao, B., Zhou, B., & Yang, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177958 · Cited by 13 · see citing works

ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease

Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14 · see citing works

Ultrasensitive Electrochemical Detection of Amyloid-β Peptide Using a Homochiral Metal–Organic Framework Binding to the l -Diphenylalanine Targeting Site

Li, R.-X., Shang, X. C., Shen, P.-Q., Zhu, Y., Gao, E., & Yue, Q. (2025) · ACS Sensors · doi:10.1021/acssensors.4c03425 · Cited by 13 · see citing works

Trichostatin A relieves anxiety-and depression-like symptoms in APP/PS1 mice

Su, Q., Ren, Y.-H., Liu, G.-W., Gao, Y., Zhang, J. Y., Zhang, J.-N., Pei, X.-X., & Li, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1333235 · Cited by 13 · see citing works

Extracellular vesicles‐based theranostics for neurodegenerative diseases

Zhao, H., Zhu, L., Wang, C., & Yang, Y. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1993 · Cited by 14 · see citing works

Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 16 · see citing works

Visualizing Endoplasmic Reticulum Stress and Autophagy in Alzheimer’s Model Cells by a Peroxynitrite-Responsive AIEgen Fluorescent Probe

Huang, L., Ma, L., Zhu, Q., Wang, H., She, G., Shi, W., & Mu, L. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00770 · Cited by 13 · see citing works

Therapeutic effects of long-term HBOT on Alzheimer's disease neuropathologies and cognitive impairment in APP/PS1 mice

Yang, C., Liu, G., Zeng, X., Xiang, Y., Chen, X., & Le, W. (2023) · Redox Biology · doi:10.1016/j.redox.2023.103006 · Cited by 12 · see citing works

Diagnosis of Alzheimer's disease: Towards accuracy and accessibility

Mu, Y., Chang, K., Chen, Y.-F., Yan, K., Wang, C.-X., & Hua, Q. (1970) · Journal of Biological Methods · doi:10.14440/jbm.2024.412 · Cited by 12 · see citing works

Dynamic prediction of goal location by coordinated representation of prefrontal-hippocampal theta sequences

Wang, Y., Wang, X., Wang, L., Li, Z., Meng, S., Zhu, N., An, X., Wang, L., Yang, J., Zheng, C., et al. (2024) · Current Biology · doi:10.1016/j.cub.2024.03.032 · Cited by 16 · see citing works

Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon

Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Hadi, N. R., Assiri, A. A., Alrouji, M., Welson, N. N., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01489-y · Cited by 12 · see citing works

Acetylcholinesterase inhibitory phloroglucinols from tropic Rhodomyrtus tomentosa

Chen, L., Luo, E.-E., Pan, Y., Liang, C.-Q., Yu, M., & Qin, X. (2024) · Phytochemistry · doi:10.1016/j.phytochem.2024.114254 · Cited by 12 · see citing works

Photocatalytic, photothermal, and blood-brain barrier-permeable carbon nanodots: A potent multifunctional scavenger for β-amyloid plaque.

Shao, X., Li, M., Yan, C., Wang, C., Wang, X., Guan, P., Hu, X., & Fan, L. (2024) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114380 · Cited by 14 · see citing works

Nitrate ameliorates myelin loss and cognitive impairment in Alzheimer’s disease through upregulation of neuronal sialin and subsequent inhibition of TPPP phosphorylation

Chen, X., Hu, G., Chang, L., Li, X., Tang, Y., Wu, Y., Zhang, R., Zhang, C., Wang, J., Wang, X., et al. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.017 · Cited by 12 · see citing works

Supramolecular Copolymerization of Glycopeptide Amphiphiles and Amyloid Peptides Improves Neuron Survival

Gao, Z., Qiu, R., Dave, D. R., Chandravanshi, P., Soares, G. P., Smith, C. S., Ortega, J. A., Palmer, L. C., Álvarez, Z., & Stupp, S. I. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00105 · Cited by 12 · see citing works

Synthetic efferocytic receptor microglia enhances anti-inflammatory clearance of amyloid-β for AD treatment in mice

Shao, L., Zhang, Y., Yang, Z., Shi, C., Yue, X., Li, C., Liu, Y., Fu, Z., Tang, C., Zhao, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads6613 · Cited by 13 · see citing works

Oxygen-enriching triphase platform for reliable sensing of femtomolar Alzheimer’s neurofilament lights

Song, Y., Kim, H., Lee, J., & Kim, K. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116431 · Cited by 11 · see citing works

Design, Synthesis, and Evaluation of New Pyrazolines As Small Molecule Inhibitors of Acetylcholinesterase

Altıntop, M. D., Sağlık, B. N., & Özdemır, A. (2024) · ACS Omega · doi:10.1021/acsomega.3c10490 · Cited by 11 · see citing works

Radix Hedysari Polysaccharides modulate the gut-brain axis and improve cognitive impairment in SAMP8 mice

Yang, S., Wang, L., Liang, X., Pei, T., Zeng, Y., Xie, B., Wang, Y., Yang, M., Wei, D., & Cheng, W. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141715 · Cited by 11 · see citing works

AΙ-Driven Drug Repurposing: Applications and Challenges

Keramida, P., Syrigos, N. K., Kouvela, M., Poulakou, G., Charpidou, A. G., & Fiste, O. (2025) · Medicines · doi:10.3390/medicines12040028 · Cited by 12 · see citing works

Indole-3-acetic acid, a potential therapeutic target in Alzheimer’s disease

Li, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.11.040 · Cited by 10 · see citing works

Potential neuroprotective benefits of plant-based fermented foods in Alzheimer's disease: an update on preclinical evidence

Chen, J., Yin, X., He, H., Lu, L. W., Wang, M., Liu, B., & Cheng, K. (2024) · Food & Function · doi:10.1039/d3fo03805j · Cited by 10 · see citing works

Activity-Based NIR Specific Fluorescent Probe Reveals the Abnormal Elevation of Prolyl Endopeptidase in Hippocampus during Alzheimer's Disease Progression

Li, H., Bian, K.-J., Wang, X.-Y., Li, X.-D., Song, P.-F., Yu, C., Ge, G.-B., Qian, X.-K., Zou, L.-W., Zhou, Y.-F., et al. (2024) · Sensors and actuators. B, Chemical · doi:10.1016/j.snb.2024.136071 · Cited by 10 · see citing works

Elucidating Microglial Heterogeneity and Functions in Alzheimer’s Disease Using Single-cell Analysis and Convolutional Neural Network Disease Model Construction

Wu, X., Liu, M., Zhang, X., Pan, X., Cui, X., Jin, J., Sun, H., Xiao, C., Tong, X., Ren, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67537-1 · Cited by 10 · see citing works

Spectral graph convolutional neural network for Alzheimer's disease diagnosis and multi-disease categorization from functional brain changes in magnetic resonance images

Alharbi, H. F., Juanatas, R. A., Hejaili, A. A., & Lim, S. (2024) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2024.1495571 · Cited by 10 · see citing works

The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage

Chen, J., Li, S., Zhang, F., Chen, J., Cai, C., Guo, Y., Lei, Z., Zeng, L., Zi, D., Shen, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02837-6 · Cited by 11 · see citing works

Exercise intervention on the brain structure and function of patients with mild cognitive impairment: systematic review based on magnetic resonance imaging studies

Xu, J., Yu, J., Gai, L., & Wang, Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1464159 · Cited by 12 · see citing works

Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies

Zetterberg, H., & Bendlin, B. B. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 379 · see citing works

Perspectivas biotecnológicas en el diagnóstico y la terapia de la enfermedad de Alzheimer

Suárez, A. H. (2021) · Hispana

Recent advances in pre-clinical diagnosis of Alzheimer’s disease

Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 12 · see citing works

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works

Morbus Alzheimer – State of the art und Blick in die Zukunft

Winkler, D. T., & Leyhe, T. (2018) · Therapeutische Umschau · doi:10.1024/0040-5930/a001020 · Cited by 2 · see citing works